In patients with suspected MI with no obstructed coronary arteries, a stratified treatment protocol was superior to standard ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company"), the leading autologous (patient's own ...
Having more-thorough workup uncovered an unexpected root cause and changed the treatment course for 76% of patients.
High cholesterol, as the name suggests, is an overabundance of cholesterol, in your blood. Though this lipid‑like substance is indispensable for tasks such as constructing cell membranes and ...
Your heart often whispers warnings before serious issues arise. Pay attention to unexplained shortness of breath during ...
Motorists are being alerted to an important date that’s fast-approaching. On social media, the DVLA Personalised Registration ...
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to no-option individuals suffering from angina, ...
In separate treatment trials, one for de novo coronary lesions and the other for in-stent restenosis, a sirolimus-eluting ...
One question, in light of FREEDOM, is how well new DES compare with CABG in patients with diabetes and multivessel disease.
Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0), the leading autologous (patient’s own) stem cell therapy company offering VesCell™ ...
Background Since the 1960s, beta blockers have been used to treat hypertrophic obstructive cardiomyopathy (HOCM), a genetic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback